07:00 , Aug 28, 2014 |  BC Innovations  |  Targets & Mechanisms

A cultured approach to ALS therapy

Although dysfunctional glial cells have long been implicated in amyotrophic lateral sclerosis progression, the precise mechanisms by which they contribute to the disease have remained poorly defined. Now, Harvard University researchers have identified a specific...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Amorfix Life Sciences Ltd board of directors update

Amorfix Life Sciences Ltd . (TSX:AMF), Mississauga, Ontario   Business: Diagnostic, Neurology   Appointed: William Wyman as chairman; he succeeds interim Chairman Neil Cashman, who remains CSO and a director  ...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Amorfix, Trellis Bioscience deal

The companies partnered to discover antibodies against misfolded CD38 protein to treat hematological malignancies, including leukemia and lymphoma. Trellis will use its CellSpot discovery platform - which uses computerized microscopy to "drastically miniaturize" a multiplexed...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Amorfix deal

Amorfix granted an undisclosed pharmaceutical company access to Amorfix's EP-AD Diagnostic CSF Test for use in Phase I trials. The pharmaceutical company will complete assay optimization and validation prior to using the assay as part...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Amorfix, Pan-Provincial Vaccine Enterprise Inc. (PREVENT) deal

Amorfix disclosed in its fiscal 1Q14 earnings for the period ending June 30 that it terminated a 2010 deal granting the not-for-profit PREVENT exclusive, worldwide rights to Amorfix's preclinical vaccines to treat and prevent amyotrophic...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Amorfix preclinical data

In an animal model of ovarian cancer, AMF-1c-120 reduced tumor volume vs. untreated controls. Data were presented at the American Association for Cancer Research meeting in Washington, D.C. Amorfix said it is conducting additional preclinical...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Amorfix, University of Texas MD Anderson Cancer Center deal

Amorfix and the university partnered to research misfolded proteins and identify targets for lung cancer therapeutics. Researchers at the cancer center will use Amorfix's anti-cancer antibodies to identify misfolded proteins expressed on the surface of...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Amorfix management update

Amorfix Life Sciences Ltd. (TSX:AMF), Mississauga, Ontario   Business: Diagnostic, Neurology   Hired: Warren Whitehead as CFO, formerly CFO of Arius Research Inc. , which Roche acquired; he replaces Janet Clennett, who becomes director of...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

Amorfix, QPS Holdings deal

Amorfix and QPS partnered to develop Amorfix's EP-AD Diagnostic CSF Test for use as both an early stage diagnostic for Alzheimer's disease and as a biomarker to facilitate AD drug development. The ultrasensitive assay uses...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Amorfix, Cangene deal

Amorfix partnered with Cangene's CNJ Holdings Inc. wholly owned subsidiary to discover and develop antibodies against disease specific epitopes (DSEs) to treat cancer using Amorfix's ProMIS technology. ProMIS is a computer-based algorithm that predicts DSEs...